Proteomic Strategies for Biomarker Discovery: From Differential Expression to Isoforms to Pathways

  • Christoph W. Turck*
  • Claudia Ditzen
  • Eser Sayan-Ayata


Proteomics technologies are improving at a great pace with the ultimate goal to allow the sensitive and comprehensive analysis of proteins in tissues and body fluids. The comparison of proteomes from two or more sources is still a challenging task but has already made significant inroads into biomarker discovery. This chapter describes strategies and platforms for biomarker discovery in mouse models and human specimens. We submit that the discovery of proteins that are differentially expressed will ultimately provide valuable information about the pathways involved in the pathobiology of psychiatric disorders.


Psychiatric Disorder Experimental Autoimmune Encephalomyelitis Mouse Quantitative Mass Spectrometry Oxidative Stress Mechanism Anxiety Phenotype 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Bipolar disorder


Cerebrospinal fluid


Dickkopf-3 related protein


Diagnostic and Statistical Manual of Mental Disorders IV


Enolase phosphatase


Glyoxalase 1


High anxiety-related behavior


International Classification of Diseases


Isobaric tags for relative and absolute quantitation


Low anxiety-related behavior


Normal anxiety-related behavior


N-methyl-d-aspartate-type excitatory amino acid receptor


Pigment epithelium-derived protein




Sodium dodecyl sulfate


Single nucleotide polymorphism


Unipolar depression


Two-dimensional polyacrylamide gel electrophoresis


  1. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders 4th edn, Text Revision, American Psychiatric Association, Washington DCGoogle Scholar
  2. Anderson NL, Anderson NG (1998) Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis 19:1853–1861PubMedCrossRefGoogle Scholar
  3. Anderson NL, Polanski M, Pieper R et al (2004) The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 3:311–326PubMedCrossRefGoogle Scholar
  4. Bernstein H-G, Müller M (1999) The cellular localization of the L-ornithine decarboxylase/polyamine system in normal and diseased central nervous systems. Prog Neurobiol 57:485–505PubMedCrossRefGoogle Scholar
  5. Bressa, GM (1994) S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand 154 (Suppl):7–14CrossRefGoogle Scholar
  6. Camp NJ, Cannon-Albright LA (2005) Dissecting the genetic aetiology of major depressive disorder using linkage analysis. Trends Mol Med 11:138–144PubMedCrossRefGoogle Scholar
  7. Chan KC, Lucas DA, Hise D et al (2004) Analysis of the human serum proteome. Clin Proteomics 1:101–225CrossRefGoogle Scholar
  8. Chen F, Wollmer MA, Hoerndli F et al (2004) Role for glyoxalase I in Alzheimer's disease. Proc Natl Acad Sci U S A 101:7687–7692PubMedCrossRefGoogle Scholar
  9. Cryan JF, Mombereau C (2004) In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatr 9:326–357CrossRefGoogle Scholar
  10. De Gruttola VG, Clax P, DeMets DL et al (2001) Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. Control Clin Trials 22:485–502PubMedCrossRefGoogle Scholar
  11. Ditzen C, Jastorff AM, Kessler MS et al (2006) Protein biomarkers in a mouse model of extremes in trait anxiety. Mol Cell Proteomics 5:1914–1920PubMedCrossRefGoogle Scholar
  12. Finn DA, Rutledge-Gorman MT, Crabbe JC (2003) Genetic animal models of anxiety. Neurogenetics 4:109–135PubMedGoogle Scholar
  13. Ftouh S, Akbar MT, Hirsch SR, de Belleroche JS (2005) Down-regulation of Dickkopf 3, a regulator of the Wnt signalling pathway, in elderly schizophrenic subjects. J Neurochem 94:520–530PubMedCrossRefGoogle Scholar
  14. Genedani S, Saltini S, Benelli A et al (2001) Influence of SAMe on the modifications of brain polyamine levels in an animal model of depression. Neuroreport 12:3939–3942PubMedCrossRefGoogle Scholar
  15. Gordon JA, Hen R (2004) Genetic approaches to the study of anxiety. Annu Rev Neurosci 27:193–222PubMedCrossRefGoogle Scholar
  16. Gross C, Hen R (2004) The developmental origins of anxiety. Nat Rev Neurosci 5:545–552PubMedCrossRefGoogle Scholar
  17. Hayes JD, Milner SW, Walker SW (1989) Expression of glyoxalase, gluthatione peroxidase and gluthatione S-transferase isoenzymes in different bovine tissues. Biochim Biophys Acta 994:21–29PubMedCrossRefGoogle Scholar
  18. Hornig M, Amsterdam JD, Kamoun M, Goodman DBP (1999) Autoantibody disturbances in affective disorders: a function of age and gender? J Affect Disord 55:29–37PubMedCrossRefGoogle Scholar
  19. Hovatta I, Tennant RS, Helton R et al (2005) Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice. Nature 438:662–666PubMedCrossRefGoogle Scholar
  20. Hyman SE (2007) Can neuroscience be integrated into the DSM-V? Nat Rev Neurosci 8:725–732PubMedCrossRefGoogle Scholar
  21. Insel TR (2007) From animal models to model animals. Biol Psychiatry 62:1337–1339PubMedCrossRefGoogle Scholar
  22. Insel TR, Quirion R (2005) J Am Med Assoc 294:2221–2224CrossRefGoogle Scholar
  23. Jastorff AM et al. (submitted)Google Scholar
  24. Junaid MA, Kowal D, Barua M et al (2004) Proteomic studies identified a single nucleotide polymorphism in glyoxalase I as autism susceptibility factor. Am J Med Genet 131:11–17PubMedCrossRefGoogle Scholar
  25. Kessler RC, Berglund P, Demler O et al (2003) The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA 289:3095–3105PubMedCrossRefGoogle Scholar
  26. Klose J (1975) Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik 26:231–243PubMedGoogle Scholar
  27. Krömer SA, Kessler MS, Milfay D et al (2005) Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J Neurosci 25:4375–4384PubMedCrossRefGoogle Scholar
  28. LaBaer J (2005) So, you want to look for biomarkers. J Proteome Res 4:1053–1059PubMedCrossRefGoogle Scholar
  29. Maccarrone G, Birg I, Malisch E et al (2004a) In-depth analysis of the human CSF proteome using protein prefractionation. Clin Proteomics J 1:333–364CrossRefGoogle Scholar
  30. Maccarrone G, Milfay D, Birg I (2004b) Mining the human CSF proteome by immunodepletion and shotgun mass spectrometry. Electrophoresis 25:2402–2412CrossRefGoogle Scholar
  31. Mathey EK, Derfuss T, Storch MK et al (2007) Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 204:2363–2372PubMedCrossRefGoogle Scholar
  32. Mill J, Petronis A (2007) Molecular studies of major depressive disorder: the epigenetic perspective. Mol Psychiatr 12:799–814CrossRefGoogle Scholar
  33. Murray CJ, Lopez AD (1997) Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 349:1436–1442PubMedCrossRefGoogle Scholar
  34. O'Farrell PH (1975) High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250:4007–4021PubMedGoogle Scholar
  35. Ross PL, Huang YN, Marchese JN et al (2004) Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3:1154–1169PubMedCrossRefGoogle Scholar
  36. Silveri MM, Parow AM, Villafuerte RA et al (2003) S-adenosyl-L-methionine: effects on brain bioenergetic status and transverse relaxation time in healthy subjects. Biol Psychiatr 54:833–839CrossRefGoogle Scholar
  37. Sköld K, Svensson M, Norrman M et al (2007) The significance of biochemical and molecular sample integrity in brain proteomics and peptidomics: Stathmin 2–20 and peptides as sample quality indicators. Proteomics 7:4445–4456PubMedCrossRefGoogle Scholar
  38. Skolnik P (1999) Antidepressants for the new millenium. Eur J Pharmacol 375:31–40CrossRefGoogle Scholar
  39. Sullivan PF, Neale MC, Kendler KS (2000) Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatr 157:1552–1562PubMedCrossRefGoogle Scholar
  40. Tanna VL, Wilson AF, Winokur G, Elston RC (1989) Linkage analysis of pure depressive disease. J Psychiatr Res 23:99–107PubMedCrossRefGoogle Scholar
  41. Thornalley PJ (1993) The glyoxalase system in health and disease. Mol Aspects Med 14:287–371PubMedCrossRefGoogle Scholar
  42. Thornalley PJ (2006) Unease on the role of glyoxalase 1 in high-anxiety-related behaviour. Trends Mol Med 12:195–199PubMedCrossRefGoogle Scholar
  43. Turck CW (2005) Understanding and treating psychiatric and neurological disorders: the benefits of cerebrospinal fluid analysis. Eur Biopharm Rev 46–49Google Scholar
  44. Turck CW, Maccarrone G, Sayan-Ayata E et al (2005) The quest for brain disorder biomarkers. J Med Invest 52 (Suppl):231–235PubMedCrossRefGoogle Scholar
  45. Uhlen M (2007) Mapping the human proteome using antibodies. Mol Cell Proteomics 6:1455–1456PubMedGoogle Scholar
  46. Wang X-F, Wang D, Zhu W et al (2003). Studies characterizing 60 kDa autoantibodies in subjects with schizophrenia. Biol Psychiatr 53:361–375CrossRefGoogle Scholar
  47. Williams K (1997) Interaction of polyamines with ion channels. Biochem J 325:289–297PubMedGoogle Scholar
  48. World Health Organization: International Statistical Classification of Diseases, 2nd edn, 10th RevisionGoogle Scholar
  49. Wu CC, MacCoss MJ, Howell KE et al (2004) Metabolic labeling of mammalian organisms with stable isotopes for quantitative proteomic analysis. Anal Chem 76:4951–4959PubMedCrossRefGoogle Scholar
  50. Yabe T, Kanemitsu K, Sanagi T et al (2005) Pigment epithelium-derived factor induces pro-survival genes through cyclic AMP-responsive element binding protein and nuclear factor kappa B activation in rat cultured cerebellar granule cells: implication for its neuroprotective effect. Neuroscience 133:691–700PubMedCrossRefGoogle Scholar
  51. Yamagishi S, Inagaki Y, Takeuchi M, Sasaki N (2004) Is pigment epithelium-derived factor level in cerebrospinal fluid a promising biomarker for early diagnosis of Alzheimer's disease? Med Hypotheses 63:115–117PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Christoph W. Turck*
    • 1
  • Claudia Ditzen
  • Eser Sayan-Ayata
  1. 1.Max Planck Institute of PsychiatryMunichGermany

Personalised recommendations